BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37174732)

  • 1. Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of the Cytokine Release Syndrome.
    Harless WW; Lewis B; Qorri B; Abdulkhalek S; Szewczuk MR
    Cells; 2023 May; 12(9):. PubMed ID: 37174732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Complexes of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Receptors: Expression in Adult but Not Fetal Lung Tissue.
    Franco R; Lillo A; Rivas-Santisteban R; Rodríguez-Pérez AI; Reyes-Resina I; Labandeira-García JL; Navarro G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
    Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Alternative Receptors for SARS-CoV-2-Induced Kidney Damage: TLR-4, KIM-1/TIM-1, and CD147.
    Habeichi NJ; Amin G; Lakkis B; Kataya R; Mericskay M; Booz GW; Zouein FA
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):8. PubMed ID: 38287815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
    Verdecchia P; Cavallini C; Spanevello A; Angeli F
    Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
    Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
    Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 down-regulates ACE2 through lysosomal degradation.
    Lu Y; Zhu Q; Fox DM; Gao C; Stanley SA; Luo K
    Mol Biol Cell; 2022 Dec; 33(14):ar147. PubMed ID: 36287912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
    Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages.
    Pantazi I; Al-Qahtani AA; Alhamlan FS; Alothaid H; Matou-Nasri S; Sourvinos G; Vergadi E; Tsatsanis C
    Front Immunol; 2021; 12():683800. PubMed ID: 34248968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
    Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
    Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
    Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
    Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
    Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
    Roshanravan N; Ghaffari S; Hedayati M
    Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme 2 (ACE2) proteins of different bat species confer variable susceptibility to SARS-CoV entry.
    Hou Y; Peng C; Yu M; Li Y; Han Z; Li F; Wang LF; Shi Z
    Arch Virol; 2010 Oct; 155(10):1563-9. PubMed ID: 20567988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.